Keros Therapeutics (KROS) Gains from Investment Securities (2020 - 2025)
Keros Therapeutics posted quarterly Gains from Investment Securities of -$14000.0 for Q4 2025, up 99.76% year-on-year from -$7008.6 in Q4 2024, and up 99.76% on a QoQ basis from -$5.7 million in Q4 2024.
Keros Therapeutics (KROS) has 6 years of Gains from Investment Securities data on file, last reported at -$14000.0 in Q4 2025.
- For the quarter ending Q4 2025, Gains from Investment Securities rose 99.76% year-over-year to -$14000.0; the trailing twelve-month figure through Dec 2025 stood at -$14000.0 (changed N/A YoY), and the FY2023 full-year result was $1.3 million, down 91.32% from the prior year.
- Gains from Investment Securities for Q4 2025 stood at -$14000.0, up from -$5.7 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $15.4 million in Q4 2022 and bottomed at -$5.7 million in Q4 2024.
- The 5-year median for Gains from Investment Securities is -$4000.0 (2023), against an average of $2.4 million.
- The widest annual swing landed in 2021, when Gains from Investment Securities jumped 40.91%; it then surged 59419.23% in 2022.
- A 5-year view of Gains from Investment Securities shows it stood at -$26000.0 in 2021, then soared by 59419.23% to $15.4 million in 2022, then tumbled by 91.3% to $1.3 million in 2023, then tumbled by 527.5% to -$5.7 million in 2024, then soared by 99.76% to -$14000.0 in 2025.
- The last three Gains from Investment Securities figures came in at -$14000.0 (Q4 2025), -$5.7 million (Q4 2024), and $5.7 million (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -14,000.00 |
| Dec 31, 2025 | -14,000.00 |
| Dec 31, 2024 | -5.74 Mn |
| Dec 31, 2024 | -5.74 Mn |
| Sep 30, 2024 | 5.74 Mn |
| Sep 30, 2024 | 5.74 Mn |
| Jun 30, 2023 | 1.34 Mn |
| Jun 30, 2023 | 1.34 Mn |
| Mar 31, 2023 | -4,000.00 |
| Mar 31, 2023 | -4,000.00 |
| Dec 31, 2022 | 15.42 Mn |
| Dec 31, 2022 | 15.42 Mn |
| Dec 31, 2021 | -26,000.00 |
| Dec 31, 2021 | -26,000.00 |
| Dec 31, 2020 | -44,000.00 |
| Dec 31, 2020 | -44,000.00 |
| Sep 30, 2020 | 44,000.00 |
| Sep 30, 2020 | 44,000.00 |